AR091908A1 - COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS - Google Patents
COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOSInfo
- Publication number
- AR091908A1 AR091908A1 ARP130102660A ARP130102660A AR091908A1 AR 091908 A1 AR091908 A1 AR 091908A1 AR P130102660 A ARP130102660 A AR P130102660A AR P130102660 A ARP130102660 A AR P130102660A AR 091908 A1 AR091908 A1 AR 091908A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzene
- preparation
- methods
- glucopiranos
- ciclopropil
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- -1 4-cyclopropyl-benzyl Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091908A1 true AR091908A1 (es) | 2015-03-11 |
Family
ID=48874313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102660A AR091908A1 (es) | 2012-07-26 | 2013-07-25 | COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9145434B2 (https=) |
| EP (3) | EP4166548A1 (https=) |
| JP (2) | JP6538556B2 (https=) |
| CN (2) | CN108774200A (https=) |
| AR (1) | AR091908A1 (https=) |
| AU (1) | AU2013294947B2 (https=) |
| BR (1) | BR112015001327B1 (https=) |
| CA (1) | CA2878698C (https=) |
| DK (2) | DK2877460T3 (https=) |
| EA (2) | EA201600506A1 (https=) |
| ES (2) | ES2694675T3 (https=) |
| FI (1) | FI3351539T3 (https=) |
| HR (2) | HRP20230081T1 (https=) |
| HU (1) | HUE061450T2 (https=) |
| LT (1) | LT3351539T (https=) |
| MX (1) | MX357906B (https=) |
| PL (2) | PL2877460T3 (https=) |
| PT (2) | PT2877460T (https=) |
| RS (1) | RS63881B1 (https=) |
| SG (1) | SG11201500574QA (https=) |
| SI (2) | SI2877460T1 (https=) |
| TW (1) | TW201418275A (https=) |
| WO (1) | WO2014016381A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
| MX376097B (es) * | 2013-12-17 | 2025-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos. |
| CA2932674C (en) * | 2014-01-23 | 2023-01-24 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| FI3721882T3 (fi) | 2014-04-01 | 2024-09-24 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimissä |
| CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
| EP4403230A3 (en) | 2014-09-25 | 2025-01-08 | Boehringer Ingelheim Vetmedica GmbH | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| KR20170060035A (ko) * | 2014-09-30 | 2017-05-31 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정 |
| CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
| AU2016310535B2 (en) | 2015-08-27 | 2021-08-19 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| WO2017206827A1 (zh) * | 2016-05-28 | 2017-12-07 | 山东轩竹医药科技有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
| MX2020006387A (es) | 2017-12-19 | 2020-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Sintesis del cocristal 1:1:1 de 1-ciano-2-(4-ciclopropil-bencil)-4 -(beta-d-glucopiranos-1-il)-benceno, l-prolina y agua. |
| EP4064854A1 (en) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors in the drying-off of non-human mammals |
| JP7423800B2 (ja) | 2020-02-17 | 2024-01-29 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用 |
| MX2024001184A (es) | 2021-07-28 | 2024-02-27 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos. |
| CN117715639A (zh) | 2021-07-28 | 2024-03-15 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途 |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| WO2023227492A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| JP2026508912A (ja) | 2023-03-06 | 2026-03-13 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 液体医薬組成物、特に１種又は複数のｓｇｌｔ－２阻害剤を含む液体医薬組成物の送達のためのシステム |
| AU2024264357A1 (en) | 2023-04-24 | 2025-10-09 | Boehringer Ingelheim Vetmedica Gmbh | Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments |
| TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
| CN121175053A (zh) | 2023-05-24 | 2025-12-19 | 勃林格殷格翰动物保健有限公司 | 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002083066A2 (en) | 2001-04-11 | 2002-10-24 | Bristol-Myers Squibb Company | Amino acid complexes of c-aryl glucosides for treatment of diabetes and method |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| BR0317929A (pt) * | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
| ATE557013T1 (de) * | 2004-03-16 | 2012-05-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| TW200745075A (en) * | 2005-09-08 | 2007-12-16 | Boehringer Ingelheim Int | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| WO2007093610A1 (en) * | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| CN101754972A (zh) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| CN103319445B (zh) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| MX2011001855A (es) * | 2008-08-22 | 2011-03-24 | Theracos Inc | Procesos para la preparacion de inhibidores de sglt2. |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
- 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
- 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
- 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
- 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
- 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
- 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
- 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
- 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
- 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091908A1 (es) | COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS | |
| NI201400061A (es) | Anticuerpos anti - phf - tau y sus usos | |
| CL2014002903A1 (es) | Composición geopolimérica de aluminosilicato; método de preparacion y sus usos. | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| BR112015002091A2 (pt) | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição | |
| CL2014002954A1 (es) | Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos. | |
| LT2776469T (lt) | Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40 | |
| DK3878495T3 (da) | Engangsinjektionspen til flere anvendelser | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| CO7121320A2 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
| PL3073959T3 (pl) | Zespól szczepiący do podawania szczepionki do młodej kury | |
| MX386584B (es) | Composiciones de liberación retardada de linaclotida. | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| CO7091179A2 (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| BR112015022347A2 (pt) | composição para vacinação, método para produzir uma composição para vacinação e uso de composição | |
| CL2013002581A1 (es) | Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios. | |
| MX379476B (es) | Derivados de manosa, un proceso para su preparación y sus usos como un fármaco. | |
| ITMI20132052A1 (it) | Impianto di alimentazione di carburante e procedimento per farlo funzionare. | |
| CR20150257A (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina | |
| BR112016007062A2 (pt) | variantes de protoxina-ii e métodos de uso | |
| CL2013003206A1 (es) | Uso de compuestos derivados de metil y etil-carboxamidas de trifluorometil-benzotiofenos, en metodos para promover el crecimiento de plantas. | |
| BR112014026564A2 (pt) | formulação, uso de uma formulação, e, processo para a preparação de uma formulação | |
| CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| BR112014027808A2 (pt) | sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |